These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21107293)

  • 1. Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
    Takiguchi Y; Seto T; Ichinose Y; Nogami N; Shinkai T; Okamoto H; Minato K; Seki N; Eguchi K; Kishi K; Nishikawa M; Watanabe K
    J Thorac Oncol; 2011 Jan; 6(1):156-60. PubMed ID: 21107293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer).
    Nokihara H; Lu S; Mok TSK; Nakagawa K; Yamamoto N; Shi YK; Zhang L; Soo RA; Yang JC; Sugawara S; Nishio M; Takahashi T; Goto K; Chang J; Maemondo M; Ichinose Y; Cheng Y; Lim WT; Morita S; Tamura T
    Ann Oncol; 2017 Nov; 28(11):2698-2706. PubMed ID: 29045553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis N; Economopoulou P; Christofyllakis C; Chelis L; Polyzos A; Vardakis N; Koinis F; Vamvakas L; Katsaounis P; Kalbakis K; Nikolaou C; Georgoulias V; Kotsakis A
    Clin Transl Oncol; 2017 Mar; 19(3):317-325. PubMed ID: 27492015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial.
    Kubota K; Sakai H; Katakami N; Nishio M; Inoue A; Okamoto H; Isobe H; Kunitoh H; Takiguchi Y; Kobayashi K; Nakamura Y; Ohmatsu H; Sugawara S; Minato K; Fukuda M; Yokoyama A; Takeuchi M; Michimae H; Gemma A; Kudoh S;
    Ann Oncol; 2015 Jul; 26(7):1401-8. PubMed ID: 25908605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
    Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
    Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
    Satouchi M; Kotani Y; Katakami N; Shimada T; Urata Y; Yoshimura S; Funada Y; Hata A; Ando M; Negoro S
    J Thorac Oncol; 2010 May; 5(5):696-701. PubMed ID: 20147856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: results of Okayama Lung Cancer Study Group (OLCSG) Trial 0503.
    Segawa Y; Kiura K; Hotta K; Takigawa N; Tabata M; Matsuo K; Yoshioka H; Hayashi H; Kawai H; Aoe K; Maeda T; Ueoka H; Tanimoto M
    J Thorac Oncol; 2010 Sep; 5(9):1430-4. PubMed ID: 20651615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
    Iranzo V; Sirera R; Carrato A; Cabrera A; Jantus E; Guijarro R; Sanmartín E; Blasco A; Gil M; Gómez-Aldaraví L; González-Larriba JL; Massuti B; Velasco A; Provencio M; Rossell R; Camps C
    Clin Transl Oncol; 2011 Jun; 13(6):411-8. PubMed ID: 21680302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    Hirsh V; Soulieres D; Duclos M; Faria S; Del Vecchio P; Ofiara L; Ayoub JP; Charpentier D; Gruber J; Portelance L; Souhami L
    J Thorac Oncol; 2007 Oct; 2(10):927-32. PubMed ID: 17909355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
    Lv C; Ma Y; Wu N; Yan S; Zheng Q; Sun Y; Li S; Fang J; Yang Y
    World J Surg Oncol; 2013 Mar; 11():76. PubMed ID: 23517534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
    Laskin JJ; Nicholas G; Lee C; Gitlitz B; Vincent M; Cormier Y; Stephenson J; Ung Y; Sanborn R; Pressnail B; Nugent F; Nemunaitis J; Gleave ME; Murray N; Hao D
    J Thorac Oncol; 2012 Mar; 7(3):579-86. PubMed ID: 22198426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, multicenter, three-stage, phase II study of s-1 in combination with cisplatin as first-line therapy for patients with advanced non-small cell lung cancer.
    Sandler A; Graham C; Baggstrom M; Herbst R; Zergebel C; Saito K; Jones D
    J Thorac Oncol; 2011 Aug; 6(8):1400-6. PubMed ID: 21673602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
    Paramanathan A; Solomon B; Collins M; Franco M; Kofoed S; Francis H; Ball D; Mileshkin L
    Clin Lung Cancer; 2013 Sep; 14(5):508-12. PubMed ID: 23792009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
    Hsu C; Kuo SH; Hu FC; Cheng AL; Shih JY; Yu CJ; Lin CC; Huang TC; Yang PC; Yang CH
    Lung Cancer; 2008 Dec; 62(3):334-43. PubMed ID: 18450322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
    Chen YM; Perng RP; Chen MC; Tsai CM; Ming-Liu J; Whang-Peng J
    Lung Cancer; 2003 May; 40(2):221-6. PubMed ID: 12711125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
    Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
    J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
    Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
    Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
    Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer.
    Govindan R; Morgensztern D; Kommor MD; Herbst RS; Schaefer P; Gandhi J; Saito K; Zergebel C; Schiller J
    J Thorac Oncol; 2011 Apr; 6(4):790-5. PubMed ID: 21325974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.